Physician profile
Matthew Westfall
NPI 1609361427
$715.98
in general payments reported to CMS, 2019-2025
15 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.19 · 2023: $141 · 2024: $97.10 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.63 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $97.13 | 2025 | Dexcom G6 Transmitter |
| Theratechnologies INC. | $88.57 | 2023 | Trogarzo, Egrifta |
| Astrazeneca Pharmaceuticals LP | $74.69 | 2024-2025 | Airsupra, Breztri |
| Gilead Sciences, INC. | $62.05 | 2025 | |
| Amgen INC. | $49.60 | 2025 | Evenity, Prolia, Tepezza |
| Pfizer INC. | $46.81 | 2024 | |
| Novo Nordisk INC | $39.19 | 2021 | |
| Sequel Med Tech, LLC | $34.06 | 2025 | Twiist |
| Almatica Pharma LLC | $32.91 | 2025 | Teriparatide, Loreev Xr |
| Exact Sciences Corporation | $19.90 | 2023 | Cologuard Collection Kit |
| Abbvie INC. | $18.92 | 2023 | Ubrelvy |
| Abbott Laboratories | $17.59 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $13.98 | 2025 | Shingrix |
| Radius Health, INC. | $13.95 | 2023 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Westfall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.